このエントリーをはてなブックマークに追加
ID 30795
JaLCDOI
フルテキストURL
著者
Matsuo, Keisuke Okayama University
Kiura, Katsuyuki Okayama University
Ueoka, Hiroshi Okayama University
Tabata, Masahiro Okayama University
Shibayama, Takuo Okayama University
Matsumura, Tadashi Okayama University
Takigawa, Nagio Okayama University
Hiraki, Shunkichi Okayama Red Cross General Hospital
Harada, Mine Okayama University
抄録

We have established an Adriamycin (ADM) -resistant small cell lung cancer (SCLC) cell line, SBC-3/ADM100, which shows multifactorial mechanisms of resistance to ADM, such as overexpression of P-glycoprotein, an enhanced detoxifying system and a decrease in topoisomerase II activity. In the present study, we confirmed that SBC-3/ADM 100 showed collateral sensitivity to methotrexate and TNP-351, a new antifolate, though this cell line showed a typical multidrug resistance (MDR) pattern. We also demonstrated a faster uptake and higher accumulation (1.3-fold) of TNP-351 in the SBC-3/ADM100 cells than those in the parent SBC-3 cells. These results explain one of the mechanisms for collateral sensitivity in the resistant cells. Furthermore, this cell line was found to have no cross-resistance to edatrexate and minimal cross-resistance to trimetrexate, 254-S (cisplatin analog), 5-fluorouracil and 4-hydroperoxyifosfamide. These drugs will have clinical importance in patients with SCLC who were previously treated with an ADM-containing regimen. Thus, antifolates, especially TNP-351 and edatrexate, can be expected to eradicate residual multidrug resistant SCLC cells selected by ADM.

キーワード
Adriamycin-resistant cell line
antifolates
small cell lung cancer
Amo Type
Article
発行日
1997-06
出版物タイトル
Acta Medica Okayama
51巻
3号
出版者
Okayama University Medical School
開始ページ
121
終了ページ
127
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Sience KeyUT